Mentions in press and media 1
| Date | Title | Description |
| 28.06.2018 | ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round | Novo Holdings has invested CHF 20 million ($20 million) in NBE Therapeutics, doubling the size of the startup’s series B round. NBE will use the money to start testing anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in solid tumor patients.... |